Neurogene Inc.
Description
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
About
CEO
Dr. Rachel L. McMinn Ph.D.
Employees
91
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
535 W 24th Street, New York, NY 10011, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 17, 2025 | — | — | — | — |
| Aug 7, 2025 | — | — | — | — |
| May 8, 2025 | — | — | — | — |
| Mar 17, 2025 | — | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 0 | — | 1 |
| Average estimate | — | 0.00 | — | -3.90 |
| Low estimate | — | 0.00 | — | -3.90 |
| High estimate | — | 0.00 | — | -3.90 |
| Last year EPS | — | — | — | -3.86 |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
-1.040%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total reported revenue | — |
| Cost of revenue | — |
| Gross profit | — |
| Operating expense | |
| Research & development | 44.39M |
| Selling general and admin | 11.19M |
| Other operating expenses | — |
| Operating income | -55.58M |
| Non operating interest income | |
| Income | 2.95M |
| Expense | 12,000 |
| Other income expense | 16.33M |
| Pretax income | -36.32M |
| Tax provision | — |
| Net income | -36.32M |
| Basic EPS | -73.84 |
| Diluted EPS | -73.84 |
| Basic average shares | 491,867 |
| Diluted average shares | 491,867 |
| EBITDA | -49.36M |
| Net income from continuing op. | -36.32M |
| Minority interests | — |
| Preferred stock dividends | — |
Balance sheet
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 222.57M | 109.27M | 101.49M |
| Current assets | |||
| Cash | — | — | — |
| Cash equivalents | — | — | — |
| Cash and cash equivalents | 148.21M | 82.02M | 70.54M |
| Other short term investments | 48.95M | — | — |
| Accounts receivable | — | — | — |
| Other receivables | 600,000 | 990,000 | 790,000 |
| Inventory | — | — | — |
| Prepaid assets | 1.50M | 1.08M | 1.91M |
| Restricted cash | — | — | — |
| Assets held for sale | — | — | — |
| Hedging assets | — | — | — |
| Other current assets | 1.10M | 630,000 | 711,000 |
| Non current assets | |||
| Properties | 13.07M | 13.39M | 10.96M |
| Land and improvements | — | — | — |
| Machinery furniture equipment | 287,000 | 289,000 | — |
| Construction in progress | 234,000 | 252,000 | 2.86M |
| Leases | 15.38M | 15.30M | 15.29M |
| Accumulated depreciation | -8.01M | -4.77M | -1.57M |
| Goodwill | — | — | — |
| Investment properties | — | — | — |
| Financial assets | — | — | — |
| Intangible assets | — | — | — |
| Investments and advances | — | — | — |
| Other non current assets | 1.37M | 87,000 | — |
| Total liabilities | 36.55M | 255.00M | 193.36M |
| Current liabilities | |||
| Accounts payable | 2.60M | 625,000 | 5.63M |
| Accrued expenses | 10.79M | 1.80M | 1.33M |
| Short term debt | 2.88M | 702,000 | 610,000 |
| Deferred revenue | — | — | — |
| Tax payable | — | — | — |
| Pensions | 5.97M | 3.36M | 3.02M |
| Other current liabilities | 737,000 | 167,000 | 267,000 |
| Non current liabilities | |||
| Long term debt | 13.37M | 3.99M | 4.60M |
| Provision for risks and charges | — | — | — |
| Deferred liabilities | — | — | — |
| Derivative product liabilities | — | — | — |
| Other non current liabilities | 203,000 | — | — |
| Shareholders equity | |||
| Common stock | — | — | 1,000 |
| Retained earnings | -187.15M | -150.84M | -95.65M |
| Other shareholders equity | — | — | — |
| Total shareholders equity | 186.02M | -145.74M | -91.88M |
| Additional paid in capital | 373.18M | 5.10M | 3.77M |
| Treasury stock | — | — | — |
| Minority interest | — | — | — |
Cash flow statement
| 2023 | |
|---|---|
| Operating Activities | |
| Net Income | -36.32M |
| Depreciation | 3.30M |
| Deferred Taxes | — |
| Stock-Based Compensation | 1.42M |
| Other Non-Cash Items | -15.69M |
| Accounts Receivable | — |
| Accounts Payable | 667,000 |
| Other Assets & Liabilities | -1.44M |
| Operating Cash Flow | -48.07M |
| Investing Activities | |
| Capital Expenditures | -321,000 |
| Net Intangibles | — |
| Net Acquisitions | — |
| Purchase of Investments | — |
| Sale of Investments | 5.00M |
| Investing Cash Flow | 25.64M |
| Financing Activities | |
| Long-Term Debt Issuance | — |
| Long-Term Debt Payments | -29,000 |
| Other Financing Charges | — |
| Financing Cash Flow | 92.31M |
| Other Cash Details | |
| End Cash Position | 148.72M |
| Income Tax Paid | — |
| Interest Paid | 12,000 |
| Free Cash Flow | -51.74M |
Error: Invalid format in Holders JSON file.
Article
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Feb 5, 2025
Article
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Feb 1, 2025
Article
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Nov 28, 2024
